Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug more accessible. AACE President Scott D. Isaacs, MD, FACP, FACE, and AACE member Karl Nadolsky, DO, FACE, DABOM, explain that these changes improve affordability for some patients without insurance coverage and expand access to a broader range of individuals. Read the full article on Health.com to learn more.